

For Health Professionals Who Care for People with Cancer

Inside This Issue:

Editor's Choice

New Programs

- **SAAVVIT** Vincristine, Temozolomide and Irinotecan for Recurrent/Refractory Ewing Sarcoma
- **SAAVVPOIT** Vincristine, Temozolomide and Oral Irinotecan for Recurrent/Refractory Ewing Sarcoma

Cancer Drug Manual®

Revised irinotecan, temozolomide, vincristine, zolbetuximab

High-Alert Medications lazertinib, quizartinib

Continuing Education

FPON Webinar Androgen Deprivation Therapy in Prostate Cancer

Benefit Drug List

New LYCARTFL3: tisagenlecleucel, SAAVVIT, SAAVVPOIT

Protocols, PPPOs and Patient Handouts

New SA SAAVVIT, SAAVVPOIT

Revised **GI** GIAJCAPOX, GIFFIRPAN **GO** GOCXCRT, GOCXPEMCRT **GU** GUBPWRT, UGUMCSPDD **HN** HNLAALTPRT **LK** ULKAMLAZIV **LU** LUAVAFAT, LUMMIPNI, LUMMIPNI3 **LY** LYABVD, LYAVDNIV, LYBENDO, LYCHOP, LYCHOPO, LYCHOPR, LYCVPO, LYCVPPABO, LYMCALT, LYOBCHLOR, ULYOGGEMOX, LYRICE **MY** MYDBLDFTI **SA** SAALT2W, SAALT3W

Resources and Contact Information

Editor's Choice

New Programs

BC Cancer Provincial Systemic Therapy has approved the following new treatment programs effective 01 August 2026. Full details of all treatment programs are available in the [Chemotherapy Protocols](#) section of the BC Cancer website.

Sarcoma

Vincristine, Temozolomide and Irinotecan for Recurrent/Refractory Ewing Sarcoma (SAAVVIT, SAAVVPOIT) – The BC Cancer Sarcoma Tumour Group is implementing treatment with vincristine, temozolomide and irinotecan (VIT) for patients with recurrent or metastatic Ewing sarcoma with progression on or after at least one prior line of therapy. Irinotecan may be administered intravenously (SAAVVIT) or orally (SAAVVPOIT). Irinotecan for oral administration should be dispensed in syringes and mixed with cranberry juice immediately prior to ingestion by the patient.

Approval of this treatment program is supported by the European randomized rEECur trial in patients with recurrent and primary refractory Ewing sarcoma.¹ The trial compared outcomes between regimens accepted as international standard of care treatment options. Median event-free survival and median overall survival were similar for high-dose ifosfamide, topotecan-cyclophosphamide and irinotecan-temozolomide regimens. Despite use of irinotecan-temozolomide only in the rEECur trial, vincristine is often added to the regimen in real world practice, and therefore VIT is also considered a standard treatment option for Ewing Sarcoma.^{2,3}

Editor's Choice

References:

1. Gupta A, Dietz MS, Riedel RF, et al. Consensus recommendations for systemic therapies in the management of relapsed Ewing sarcoma: a report from the National Ewing Sarcoma Tumor Board. *Cancer* 2024;130:4028-4039. <https://doi.org/10.1002/cncr.35537>
2. Palmerini E, Jones RL, Setola E, et al. Irinotecan and temozolomide in recurrent Ewing sarcoma: an analysis in 51 adult and pediatric patients. *Acta Oncologica* 2018;57(7):958-964. <https://doi.org/10.1080/0284186X.2018.1449250>
3. Raciborska A, Bilska K, Drabko K, et al. Vincristine, irinotecan, and temozolomide in patients with relapsed and refractory Ewing sarcoma. *Pediatr Blood Cancer* 2013;60:1621-1625. <https://doi.org/10.1002/pbc.24621>

Cancer Drug Manual[®]

All documents are available in the [Cancer Drug Manual[®]](#) on the BC Cancer website.

Revised Documents

Irinotecan Monograph and Chemotherapy Preparation and Stability Chart

Uses: updated with Ewing sarcoma

Interactions paragraphs: added grapefruit juice for oral irinotecan

Solution Preparation and Compatibility: added *Additional information* for irinotecan oral solution

Dosage Guidelines: updated with new BC Cancer protocols (SAAVVIT, SAAVVPOIT)

Chemotherapy Preparation and Stability Chart:

Product Stability: updated stability information for Accord Brand

Temozolomide Monograph

Uses: updated with Ewing sarcoma

Dosage Guidelines: updated with new BC Cancer protocols (SAAVVIT, SAAVVPOIT)

Vincristine Monograph

Uses: updated with Ewing sarcoma

Dosage Guidelines: updated with new BC Cancer protocols (SAAVVIT, SAAVVPOIT)

Zolbetuximab Monograph and Chemotherapy Preparation and Stability Chart

Supply and Storage: added 300 mg vial size

Chemotherapy Preparation and Stability Chart:

Drug & Strength column: added 300 mg vial size

Reconstitute With column: added reconstitution information for 300 mg vial size

Oncology High-Alert Medications

Lazertinib and **quizartinib** have been added to the [Oncology High-Alert Medications](#) list.

Continuing Education

Family Practice Oncology Network | Androgen Deprivation Therapy in Prostate Cancer

The Family Practice Oncology Network (FPON) is pleased to announce a webinar with Dr. Justin Bhullar on **Androgen Deprivation Therapy in Prostate Cancer: Mitigating Treatment-Related Toxicities and Addressing Questions on Testosterone Therapy and Prostate Cancer Risk**. The webinar takes place Thursday 17 September 2026, from 0800-0900h, as part of the accredited, complimentary FPON webcasts.

By the end of the session, participants will be able to:

- Explain how the treatment of prostate cancer contributes to symptoms of androgen deprivation.
- Recognize symptoms related to androgen deprivation therapy.
- Apply management strategies for androgen deprivation-related symptoms.
- Discuss whether testosterone therapy impacts prostate cancer risk.

For more information and link to registration, visit:

[FPON Webinar | Androgen Deprivation Therapy in Prostate Cancer | UBC CPD](#)

Benefit Drug List

New Programs

The following treatment programs have been added to the BC Cancer [Benefit Drug List](#) effective 01 August 2026:

Protocol Title	Protocol Code	Benefit Status
tisagenlecleucel (KYMRIAH): third-line treatment of adults with follicular lymphoma (grade 1, 2 or 3a) and marginal zone lymphoma	LYCARTFL3	Restricted
Treatment of Recurrent/Refractory Ewing Sarcoma using Vincristine, Temozolomide and Irinotecan	SAAVVIT	Class I
Treatment of Recurrent/Refractory Ewing Sarcoma using Vincristine, Temozolomide and Oral Irinotecan	SAAVVPOIT	Class I

Highlights of New & Revised Protocols, PPPOs and Patient Handouts

BC Cancer Treatment Protocols, Provincial Preprinted Orders (PPPOs) and Patient Handouts are revised periodically. New, revised or deleted protocols, PPPOs and patient handouts for this month are listed below, with document revisions indicated in the respective columns. Protocol codes for treatment requiring BC Cancer Compassionate Access Program (CAP) approval are prefixed with the letter **U**.

NEW Protocols, PPPOs and Patient Handouts (*new documents checked ☑*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
SAAVVIT	Treatment of Recurrent/Refractory Ewing Sarcoma using Vincristine, Temozolomide and Irinotecan	☑	☑	☑
SAAVVPOIT	Treatment of Recurrent/Refractory Ewing Sarcoma using Vincristine, Temozolomide and Oral Irinotecan	☑	☑	☑

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
GI Gastrointestinal				
GIAJCAPOX	Adjuvant Combination Chemotherapy for Stage III and Stage IIB Colon Cancer using Oxaliplatin and Capecitabine	---	---	<i>Minor formatting</i>
GIFFIRPAN	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer using Irinotecan, Fluorouracil, Leucovorin and Panitumumab	<i>Eligibility updated; hyperlink and units of measure clarified</i>	<i>Units of measure clarified</i>	---
GO Gynecologic Oncology				
GOCXCRT	Treatment of High-Risk Squamous Carcinoma, Adenocarcinoma, or Adenosquamous Carcinoma of the Cervix with Concurrent Cisplatin and Radiation	<i>Treatment updated; units of measure clarified</i>	<i>Units of measure clarified</i>	---
GOCXPEMCRT	Treatment of Locally Advanced Cervical Cancer with Pembrolizumab, Cisplatin and Radiation Therapy	<i>Treatment updated</i>	---	---
GU Genitourinary				
GUBPWRT	Treatment of Locally Advanced Bladder Cancer with Weekly Cisplatin and Concurrent Radiation	<i>Eligibility and units of measure clarified</i>	<i>Units of measure clarified</i>	---
UGUMCSPDD	Treatment of Metastatic Castration-Sensitive Prostate Cancer using Darolutamide and Docetaxel	<i>Notes updated; units of measure clarified; physician contact information updated</i>	<i>Units of measure clarified</i>	---

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
HN Head and Neck				
HNLAALPRT	Locally Advanced (Alternate) Head and Neck Cancer using Cisplatin during Radiation Therapy	<i>Treatment and physician contact information updated; units of measure clarified</i>	<i>Units of measure clarified</i>	---
LK Leukemia and BMT				
ULKAMLAZIV	Therapy of Acute Myeloid Leukemia using Azacitidine and Ivosidenib	<i>Premedications and physician contact information updated</i>	<i>Pre-chemo metrics reformatted</i>	---
LU Lung				
LUAVAFAT	First-Line Treatment of Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) with Afatinib	---	<i>Tablets package size updated; tests clarified</i>	---
LUMMIPNI	Treatment of Malignant Mesothelioma using Ipilimumab and Nivolumab	<i>Eligibility and treatment updated</i>	---	---
LUMMIPNI3	Treatment of Malignant Mesothelioma using Ipilimumab and 3-Weekly Nivolumab	<i>Eligibility, treatment and contact information updated</i>	---	---
LY Lymphoma				
LYABVD	Treatment of Hodgkin Lymphoma with Doxorubicin, Bleomycin, Vinblastine and Dacarbazine	<i>Pegfilgrastim option added; contact information updated; tests, treatment and eligibility clarified</i>	---	<i>Protocol code, treatment, instructions and side effects updated and clarified</i>
LYAVDNIV	Treatment of Hodgkin Lymphoma with Doxorubicin, Vinblastine, Dacarbazine and Nivolumab	<i>Pegfilgrastim option added; contact information updated</i>	---	---
LYBENDO	Treatment of Rituximab-Refractory Follicular Lymphoma with Bendamustine in Combination with Obinutuzumab	<i>Pegfilgrastim option added; contact information updated</i>	---	---
LYCHOP	Treatment of Lymphoma with Doxorubicin, Cyclophosphamide, Vincristine and Prednisone	<i>Pegfilgrastim option added; contact information updated</i>	---	<i>Protocol code, treatment, side effects and instructions updated and clarified</i>
LYCHOPO	Treatment of Rituximab-Refractory Follicular Lymphoma with Doxorubicin, Cyclophosphamide, Vincristine, Prednisone and Obinutuzumab	<i>Pegfilgrastim option added; contact information updated</i>	---	---

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
LYCHOPR	Treatment of Lymphoma with Doxorubicin, Cyclophosphamide, Vincristine, Prednisone and Rituximab	<i>Pegfilgrastim option added</i>	---	<i>BC Cancer logo, protocol code, treatment and side effects updated and clarified</i>
LYCVPO	Treatment of Rituximab-Refractory Follicular Lymphoma with Cyclophosphamide, Vincristine, Prednisone and Obinutuzumab	<i>Pegfilgrastim option added; contact information updated</i>	---	---
LYCVPPABO	Treatment of Hodgkin Lymphoma with Cyclophosphamide, Vinblastine, Procarbazine, Prednisone, Doxorubicin, Vincristine and Bleomycin	<i>Pegfilgrastim option added; contact information and dose modifications updated; treatment clarified</i>	---	---
LYMCALT	Treatment of Mantle Cell Lymphoma with Doxorubicin, Cyclophosphamide, Vincristine, Prednisone and Rituximab (LYCHOPR) Alternating with Dexamethasone, Cytarabine, Platinum and Rituximab (LYDHAPR)	<i>Dose modifications updated</i>	---	<i>Treatment, instructions and side effects updated and clarified</i>
LYOBCHLOR	Treatment of Previously Untreated Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma with Obinutuzumab and Chlorambucil	<i>Pegfilgrastim option added; contact information updated</i>	---	---
ULYOGGEMOX	Treatment of Lymphoma using Obinutuzumab, Glofitamab, Gemcitabine and Oxaliplatin	<i>Treatment updated</i>	Cycles 2-8 PPPO Treatment and return appointment orders updated	---
LYRICE	Treatment of Relapsed or Refractory Advanced Stage Aggressive B-Cell Non-Hodgkin's Lymphoma with Ifosfamide, Carboplatin, Etoposide and Rituximab	<i>Pegfilgrastim option added</i>	---	---
MY Myeloma				
MYDBLDFTI	Treatment of Previously Untreated Multiple Myeloma Ineligible for Stem Cell Transplant using Daratumumab, Bortezomib, Lenalidomide and Dexamethasone	<i>Physician contact information updated</i>	---	---
SA Sarcoma				
SAALT2W	Etoposide, Ifosfamide-Mesna (SAIME) Alternating with Vincristine, Doxorubicin and Cyclophosphamide (with or without Mesna) (SAVAC or SAVACM) with Filgrastim Support at TWO Weekly Intervals for Newly Diagnosed Ewing Sarcoma/Ewing Family of Tumours, Desmoplastic Intra-Abdominal Small Round Blue Cell Tumour or Rhabdomyosarcoma	<i>Doxorubicin total dose corrected; units of measure clarified; physician contact information updated</i>	---	---

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
SAALT3W	Etoposide, Ifosfamide-Mesna (SAIME) Alternating with Vincristine, Doxorubicin and Cyclophosphamide (with or without Mesna) (SAVAC or SAVACM) with Filgrastim Support at THREE Weekly Intervals for Newly Diagnosed Ewing Sarcoma/Ewing Family of Tumours, Desmoplastic Intra-Abdominal Small Round Blue Cell Tumour or Rhabdomyosarcoma	<i>Doxorubicin total dose corrected; units of measure clarified; physician contact information updated</i>	---	---

Resources and Contact Information

Resource	Phone	Email / Toll Free / Fax
Systemic Therapy Update: www.bccancer.bc.ca/health-professionals/clinical-resources/systemic-therapy/systemic-therapy-update		
Systemic Therapy Update Editor	604-877-6000 x 672649	bulletin@bccancer.bc.ca
Oncology Drug Information Cancer Drug Manual Editor	604-877-6275	druginfo@bccancer.bc.ca
Pharmacy Oncology Certification	250-712-3900 x 686820	rxchemocert@bccancer.bc.ca
CAP – Compassionate Access Program	604-877-6277	cap_bcca@bccancer.bc.ca fax 604-708-2026
OSCAR – Online System for Cancer Drugs Adjudication and Reimbursement	888-355-0355	oscar@bccancer.bc.ca fax 604-708-2051
Library/Cancer Information	604-675-8003	toll free 888-675-8001 x 8003 requests@bccancer.bc.ca
Library Document Delivery	604-675-8002	requests@bccancer.bc.ca
Pharmacy Professional Practice Professional Practice, Nursing Provincial Systemic Therapy Network	604-877-6000 x 672247 604-877-6000 x 672623 604-877-6000 x 672247	mclin@bccancer.bc.ca BCCancerPPNAdmin@phsa.ca ProvincialSystemicOffice@bccancer.bc.ca
BC Cancer – Abbotsford BC Cancer – Kelowna BC Cancer – Prince George BC Cancer – Surrey BC Cancer – Vancouver BC Cancer – Victoria	604-851-4710 250-712-3900 250-645-7300 604-930-2098 604-877-6000 250-519-5500	toll free 877-547-3777 toll free 888-563-7773 toll free 855-775-7300 toll free 800-523-2885 toll free 800-663-3333 toll free 800-670-3322
Community Oncology Network (CON) sites: To update your contact information, please contact: bulletin@bccancer.bc.ca		

Editorial Review Board

Anne Dar Santos, BScPharm, PharmD (Editor)
Jelena Mucovic, BScPharm (Assistant Editor)
Mário de Lemos, PharmD, MSc(Oncol)
Alina Gerrie, MD, MPH, FRCPC

Yuna Jang, RN
Michelle Lafreniere, BScN, RN
Alison Pow, BScPharm